Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Jul 19 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-0.29 Insider Own19.01% Shs Outstand35.48M Perf Week-4.74%
Market Cap64.83M Forward P/E- EPS next Y-0.54 Insider Trans0.00% Shs Float29.01M Perf Month-14.22%
Income-8.72M PEG- EPS next Q-0.06 Inst Own10.92% Short Float0.25% Perf Quarter-19.20%
Sales0.00M P/S- EPS this Y19.35% Inst Trans-3.96% Short Ratio0.65 Perf Half Y75.73%
Book/sh0.25 P/B7.26 EPS next Y-116.00% ROA-79.80% Short Interest0.07M Perf Year119.98%
Cash/sh0.26 P/C7.00 EPS next 5Y- ROE-92.02% 52W Range0.52 - 3.35 Perf YTD201.67%
Dividend Est.- P/FCF- EPS past 5Y25.05% ROI-95.92% 52W High-45.97% Beta1.61
Dividend TTM- Quick Ratio8.70 Sales past 5Y-23.65% Gross Margin-378.57% 52W Low248.08% ATR (14)0.14
Dividend Ex-Date- Current Ratio8.70 EPS Y/Y TTM28.39% Oper. Margin0.00% RSI (14)42.62 Volatility5.17% 7.91%
Employees37 Debt/Eq0.04 Sales Y/Y TTM-100.00% Profit Margin- Recom1.00 Target Price10.00
Option/ShortYes / Yes LT Debt/Eq0.02 EPS Q/Q27.76% Payout- Rel Volume0.30 Prev Close1.87
Sales Surprise- EPS Surprise183.33% Sales Q/Q- EarningsMay 10 AMC Avg Volume109.81K Price1.81
SMA20-2.74% SMA50-14.47% SMA20033.23% Trades Volume32,650 Change-3.21%
Date Action Analyst Rating Change Price Target Change
Mar-22-21Initiated Aegis Capital Buy $12
Jul-08-24 03:53PM
Jul-02-24 05:05PM
Jun-25-24 04:37PM
Jun-20-24 12:38PM
06:47AM Loading…
Jun-17-24 01:00PM
Jun-10-24 07:22PM
Jun-07-24 07:30AM
Jun-03-24 09:40AM
May-23-24 06:45AM
May-16-24 09:40AM
May-15-24 08:00AM
May-13-24 07:00AM
08:53PM Loading…
May-10-24 08:53PM
Apr-26-24 06:00PM
Apr-18-24 06:15PM
Apr-15-24 03:43PM
Apr-12-24 09:40AM
Apr-09-24 09:09AM
Apr-08-24 08:30AM
Mar-26-24 08:30AM
Mar-24-24 03:54PM
Mar-20-24 08:00AM
Mar-08-24 04:05PM
Mar-04-24 08:30AM
Jan-30-24 08:30AM
Jan-03-24 08:00AM
08:00AM Loading…
Dec-26-23 08:00AM
Nov-29-23 08:30AM
Nov-14-23 07:30AM
Nov-09-23 02:30PM
Oct-16-23 08:00AM
Sep-13-23 01:18PM
Sep-12-23 08:30AM
Sep-05-23 08:00AM
Aug-16-23 08:30AM
Aug-11-23 04:05PM
Jun-07-23 07:30AM
May-07-23 08:10AM
May-05-23 05:15PM
May-04-23 10:00AM
May-03-23 09:34AM
Apr-26-23 08:30AM
Apr-03-23 07:00AM
Mar-31-23 05:15PM
Mar-23-23 09:27AM
Mar-10-23 08:05AM
Feb-20-23 08:34AM
Feb-15-23 10:00AM
Feb-13-23 09:00AM
Feb-10-23 06:00PM
Feb-02-23 06:00PM
Jan-27-23 06:00PM
Jan-25-23 06:15PM
Jan-18-23 06:15PM
Nov-16-22 07:27AM
Nov-10-22 05:45PM
Oct-06-22 07:00AM
Oct-01-22 08:28AM
Sep-21-22 08:30AM
Sep-12-22 04:30PM
Aug-11-22 06:30AM
Jul-26-22 07:30AM
Jul-18-22 09:11AM
Jun-17-22 05:00PM
May-16-22 08:00AM
May-12-22 08:00AM
May-05-22 08:00AM
Apr-28-22 08:00AM
Apr-08-22 05:02PM
Mar-22-22 08:00AM
Mar-16-22 06:14AM
Mar-08-22 06:30AM
Mar-03-22 09:50AM
Feb-17-22 08:30AM
Jan-04-22 08:30AM
Nov-10-21 08:30AM
Oct-28-21 08:30AM
Oct-06-21 03:47PM
Sep-17-21 08:09AM
Sep-01-21 08:30AM
Aug-23-21 11:00AM
Aug-19-21 09:04AM
Aug-16-21 06:30AM
Aug-13-21 04:30PM
Aug-06-21 10:20AM
Aug-02-21 08:30AM
Jun-28-21 03:15PM
Jun-25-21 06:23PM
Jun-24-21 12:38PM
Entera Bio Ltd. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of orally delivered large molecule therapeutics. It s pipeline include PTH, GLP-E, and hGh, The company was founded on September 30, 2009 and is headquartered in Jerusalem, Israel.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Taitel HayaDirectorJan 12 '24Buy0.999,5009,40535,115Jan 16 08:00 AM
Taitel HayaDirectorJan 10 '24Buy0.777,6155,86425,615Jan 11 06:14 PM
LIEBERMAN GERALD MDirectorDec 22 '23Buy0.7123,95217,006226,961Dec 27 05:00 PM
Toledano Miranda JayneChief Executive OfficerDec 22 '23Buy0.7123,95217,006110,752Dec 27 08:27 AM
Taitel HayaDirectorAug 22 '23Buy0.6218,00011,21618,000Aug 24 08:12 AM
Ellis SeanDirectorAug 21 '23Buy0.6040,00024,000102,100Aug 22 09:20 AM
LIEBERMAN GERALD MDirectorAug 21 '23Buy0.5920,00011,784214,209Aug 23 09:28 AM